2 results match your criteria: "Affiliated Hospital of Beihua University Jilin 132000[Affiliation]"

Article Synopsis
  • Skin toxicity, particularly rash and pruritus, is a common side effect of chemotherapy drugs nab-paclitaxel and paclitaxel, prompting a study to evaluate their incidence.
  • A systematic review and meta-analysis of 11 studies involving 971 patients revealed that nab-paclitaxel has a higher incidence of rash compared to paclitaxel, particularly in all grades, while the incidence of pruritus was not significantly different between the two drugs.
  • The findings suggest a need for careful monitoring and management of rash in patients receiving nab-paclitaxel to mitigate the associated risks.
View Article and Find Full Text PDF

Purpose: To understand E6 associated protein (E6-AP)'s influence on prostate cancer cell proliferation and infiltration, thus providing the theoretical basis for developing therapeutic drugs for prostate cancer metastasis to the bone.

Methods: Electroporation was performed to introduce linear regulatory plasmid PrevTet-off-in and conjugative plasmid PrevTRE2-flag-E6AP into prostate cancer cell line to establish wild-type E6-AP over-expressing transgenic LNCaP cell line; Western blot assay was adopted to examine expression levels of E6-AP, mammalian target of rapamycin (mTOR), protein kinase B (Akt), and phosphoinositide 3-kinase (PI3K); PI3K inhibitor LY294002 was applied to all the cells and MTT assay was used to measure cell proliferation; Matrigel invasion chamber assay was adopted to detect cancer cell migration and invasion.

Results: Stably transfected LNCaP cells that over expressed E6-AP had higher expression levels of PI3K, Akt, and mTOR than control LNCaP cells; MTT assay showed that E6-AP-LNCaP cells were more responsive to the inhibitory effect of LY294002; Matrigel invasion chamber assay revealed increased cell crawling and adhesiveness of E6-AP-LNCaP cells.

View Article and Find Full Text PDF